Zacks Investment Research lowered shares of Apellis Pharmaceuticals (NASDAQ:APLS) from a hold rating to a sell rating in a report issued on Monday.

According to Zacks, “Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. “

A number of other equities research analysts have also recently issued reports on APLS. B. Riley lifted their price target on shares of Apellis Pharmaceuticals from $27.00 to $40.00 and gave the company a buy rating in a research note on Thursday, September 13th. Cantor Fitzgerald set a $53.00 target price on shares of Apellis Pharmaceuticals and gave the stock a buy rating in a research note on Monday, October 1st. ValuEngine raised shares of Apellis Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, November 1st. JPMorgan Chase & Co. lowered their target price on shares of Apellis Pharmaceuticals from $38.00 to $34.00 and set an overweight rating on the stock in a research note on Wednesday, November 14th. Finally, Citigroup lifted their target price on shares of Apellis Pharmaceuticals from $34.00 to $40.00 and gave the stock a buy rating in a research note on Thursday, December 6th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Apellis Pharmaceuticals currently has an average rating of Buy and an average target price of $38.67.

Apellis Pharmaceuticals stock opened at $14.00 on Monday. Apellis Pharmaceuticals has a 1 year low of $11.45 and a 1 year high of $32.00. The firm has a market capitalization of $783.46 million, a P/E ratio of -3.81 and a beta of 0.26. The company has a debt-to-equity ratio of 0.14, a quick ratio of 14.91 and a current ratio of 14.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.05. As a group, analysts forecast that Apellis Pharmaceuticals will post -2.38 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Hillhouse Capital Management Ltd. boosted its stake in Apellis Pharmaceuticals by 203.0% during the 2nd quarter. Hillhouse Capital Management Ltd. now owns 4,328,289 shares of the company’s stock worth $95,222,000 after purchasing an additional 2,899,718 shares during the last quarter. BlackRock Inc. boosted its stake in Apellis Pharmaceuticals by 1.9% during the 3rd quarter. BlackRock Inc. now owns 2,853,195 shares of the company’s stock worth $50,730,000 after purchasing an additional 54,227 shares during the last quarter. Vanguard Group Inc. boosted its stake in Apellis Pharmaceuticals by 5.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,414,900 shares of the company’s stock worth $25,157,000 after purchasing an additional 72,610 shares during the last quarter. Vanguard Group Inc boosted its stake in Apellis Pharmaceuticals by 5.4% during the 3rd quarter. Vanguard Group Inc now owns 1,414,900 shares of the company’s stock worth $25,157,000 after purchasing an additional 72,610 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in Apellis Pharmaceuticals by 44.5% during the 3rd quarter. Victory Capital Management Inc. now owns 1,347,753 shares of the company’s stock worth $23,963,000 after purchasing an additional 415,000 shares during the last quarter. 55.94% of the stock is currently owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.

Read More: Bear Market – How and Why They Occur

Get a free copy of the Zacks research report on Apellis Pharmaceuticals (APLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.